Adverts
MONDAY, October 3, 2022 (HealthDay News) — For a sample of 60 drugs, investments in research and development do not explain the variation in list prices, according to a study published online September 26 in JAMA Network Open.
Olivier J. Wouters, Ph.D., of the London School of Economics and Political Science, and colleagues conducted a cross-sectional study analyzing 60 drugs approved by the U.S. Food and Drug Administration between January 1, 2009, and December 31, 2018, to examine the association between treatment costs and investments in research and development.
The researchers observed no association between estimated research and development investments and log-adjusted treatment costs based on list prices at launch or net prices one year after launch. When 2021 prices were used to estimate treatment costs, this result held. No association was observed between estimated research and development investments and log-adjusted treatment at launch in the fully adjusted model or from 2021 in the linear regression models.
“"Pharmaceutical companies must provide more data to support claims that high drug prices are necessary to recoup investments in research and development if this argument continues to be used to justify high prices," the authors write.
One author revealed financial ties to the pharmaceutical industry.
